The FDA has granted approval to two drugs for the treatment of diarrhea-predominant irritable bowel syndrome in adults. Actavis' eluxadoline, or Viberzi, reduces bowel contractions and constipation risk, while Valeant Pharmaceuticals' rifaximin, or Xifaxan, was previously approved as a treatment for traveler's diarrhea. The approvals were backed by trial data showing the drugs improved IBS-D symptoms more effectively than placebo.
A study in The American Journal of Gastroenterology found constipation-predominant irritable bowel syndrome and chronic idiopathic constipation may not be separate diseases but instead exist on the same disease spectrum. University of Michigan researchers said the specific abdominal symptoms common to both conditions identify the patients most severely affected by constipation. Read the abstract.
Two studies from the GI Motility program at Cedars Sinai Medical Center in Los Angeles found that irritable bowel syndrome patients had higher levels of anti-vinculin antibodies than those without the condition, suggesting the molecule could be used as a predictive biomarker, and that neomycin given with rifaximin was better than neomycin and a placebo at reducing constipation symptoms. The research was presented at the ACG Annual Scientific Meeting.
Kathi Thiboutot was diagnosed with celiac disease in 1990, and her store, Healthy Haven, in Tiverton, Mass., offers some 950 gluten-free products and a lot of good information. Thiboutot and her store will be featured on the TV segment "Smart Woman" this month.
Researchers studied more than 52,000 Twitter updates, or tweets, that mentioned antibiotics and found about 700 gave incorrect information or bad advice. Study authors said people should take what they read with a grain of salt and get a physician's opinion.